hrs4r
 I want to donate

GEMMA OSCA GELIS

Firma
GEMMA OSCA-GELIS
Position
Investigador/a Post-doctoral – R2
Postdoctoral Researchers – R2

Projectes

Codi oficial: 6822ZB3KJ Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA (AGAUR)

Publicacions

Auñón C, Sanvisens A, Turon E, Vidal-Vila A, Puigdemont M, Osca-Gelis G, Eraso A, Marcos-Gragera R

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018).

CANCER MEDICINE, 2023, 12, 12343-12353 dx.doi.org/10.1002/cam4.5935
Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Frontiers in Immunology, 2023, 14, 1158105-1158105 dx.doi.org/10.3389/fimmu.2023.1158105
Díaz-Santa J, Rodríguez-Romanos R, Coll R, Osca G, Pratcorona M, González-Bártulos M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Díez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall-Llovera F, Esteve J, Sierra J, Gallardo D, “Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielo

5 '-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics

EUROPEAN JOURNAL OF HAEMATOLOGY, 2022, 109, 755-764 dx.doi.org/10.1111/ejh.13862
Rubió-Casadevall J, Carbó-Bagué A, Puigdemont M, Osca-Gelis G, Oliveras G, Vilar-Coromina N, Ferrer-Fabrega B, Urban A, Llobet-Roma M, Martín-Romero F, Perez-Bueno F, Marcos-Gragera R

Population-based analysis of the prevalence of BRAF mutation in patients diagnosed with cutaneous melanoma and its significance as a prognostic factor

EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31, 616-622 dx.doi.org/10.1684/ejd.2021.4136
Díaz-Santa J, Rodríguez-Romanos R, Osca G, Pratcorona M, Garrido A, Coll R, Moret C, Escoda L, Tormo M, Heras I, Arnan M, Vives S, Salamero O, Lloveras N, Bargay J, Sampol A, Cruz D, Garcia A, Quiñones T, Esteve J, Sierra J, Gallardo D, on the behalf of CETLAM Group

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

Leukemia, 2020, 34, 2925-2933 dx.doi.org/10.1038/s41375-020-0784-2
Fort Culillas, R., Carmona Garcia, C., Osca Geli, G., Marcos-Gragera, R., Puigdemont Guinart, M., Biarnes Costa, J., Lopez-Ben, S., Garcia Velasco, A., Guardeno Sanchez, R.

Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain

ANNALS OF ONCOLOGY, 2020, 31, 169-169 dx.doi.org/10.1016/j.annonc.2020.04.325
Solans M, Osca-Gelis G, Comas R, Roncero JM, Gallardo D, Marcos-Gragera R, Saez M

Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain

CANCER CAUSES & CONTROL, 2018, 29, 379-382 dx.doi.org/10.1007/s10552-018-1004-5
Rubió-Casadevall J, Borràs JL, Carmona C, Ameijide A, Osca G, Vilardell L, Izquierdo A, Galceran J, Marcos-Gragera R

Temporal trends of incidence and survival of sarcoma of digestive tract including Gastrointestinal Stromal Tumours (GIST) in two areas of the north-east of Spain in the period 1981-2005: a population-based study.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2014, 16, 660-667 dx.doi.org/10.1007/s12094-013-1131-0
Puig-Vives M, Osca-Gelis G, Camprubí-Font C, Vilardell ML, Izquierdo A, Marcos-Gragera R

Proporción de cáncer de mama en mujeres de 50 a 69 años de Girona según el método de detección.

MEDICINA CLINICA, 2014, 143, 300-302 dx.doi.org/10.1016/j.medcli.2013.09.042
Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, Marcos-Gragera R, Maynadié M, Monnereau A, Osca-Gelis G, Visser O, De Angelis R, EUROCARE-5 Working Group

Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.

LANCET ONCOLOGY, 2014, 15, 931-942 dx.doi.org/10.1016/S1470-2045(14)70282-7

Formulari de contacte

About IDIBGI!

menu